Nutritional formulations containing octenyl succinate anhydride-modified tapioca starch
The present invention relates to a nutritional formulation comprising a lipid source, a carbohydrate source, a protein equivalent source, and an emulsifying agent comprising OSA-modified tapioca starch which contains less than about 0.05% non-protein nitrogen.
1 . A nutritional formulation comprising a lipid source, a carbohydrate source, a protein equivalent source, and an emulsifying agent comprising OSA-modified tapioca starch which contains less than about 0.05% non-protein nitrogen.
2 . The nutritional formulation according to claim 1 , wherein the nutritional formulation is protein-free.
3 . The nutritional formulation according to claim 1 , wherein the protein equivalent source is amino acids.
4 . The nutritional formulation according to claim 1 , wherein the protein equivalent source is hydrolyzed protein.
5 . The nutritional formulation according to claim 4 , wherein the protein is partially hydrolyzed.
6 . The nutritional formulation according to claim 4 , wherein the protein is extensively hydrolyzed.
7 . The nutritional formulation according to claim 1 , wherein the protein equivalent source is selected from the group consisting of soy protein, egg protein, whey protein and casein protein.
8 . The nutritional formulation according to claim 1 , wherein the protein equivalent source is intact protein.
9 . The nutritional formulation according to claim 1 , wherein the OSA-modified tapioca starch contains less than about 0.045% non-protein nitrogen.
10 . The nutritional formulation according to claim 1 , wherein the OSA-modified tapioca starch contains less than about 0.040% non-protein nitrogen.
11 . The nutritional formulation according to claim 1 , wherein the OSA-modified tapioca starch is protein-free.
12 . The nutritional formulation according to claim 1 , wherein OSA-modified tapioca starch is the sole emulsifying agent.
13 . The nutritional formulation according to claim 1 , wherein the OSA-modified tapioca starch is intact.
14 . The nutritional formulation according to claim 1 , wherein the nutritional formulation is hypoallergenic.
15 . The nutritional formulation according to claim 1 , wherein the pH of the nutritional formulation is between about 4 and 5.
16 . The nutritional formulation according to claim 1 , wherein the level of OSA-modified tapioca starch in the nutritional formulation comprises between about 2% and 15% of the formula.
17 . The nutritional formulation according to claim 1 , wherein the level of OSA-modified tapioca starch in the nutritional formulation comprises about 5% of the formula.
18 . The nutritional formulation according to claim 17 , wherein the OSA modified tapioca starch contributes 4% of the total caloric content.
19 . The nutritional formulation according to claim 1 , wherein the form of the nutritional formulation is selected from the group consisting of a liquid, a powder and a ready-to-use formulation.
20 . The nutritional formulation according to claim 1 additionally comprising a source of DHA.
21 . The nutritional formulation according to claim 20 , wherein the source of DHA comprises single-celled organisms.
22 . The nutritional formulation according to claim 20 , wherein the nutritional formulation comprises DHA in an amount of from about 2 mg to about 100 mg per 100 kcal nutritional formulation.
23 . The nutritional formulation according to claim 20 , wherein the nutritional formulation comprises DHA in an amount of from about 5 mg to about 75 mg per 100 kcal nutritional formulation.
24 . The nutritional formulation according to claim 20 , wherein the nutritional formulation comprises DHA in an amount of from about 15 mg to about 60 mg per 100 kcal nutritional formulation.
25 . The nutritional formulation according to claim 1 additionally comprising a source of DHA and a source of ARA.
26 . The nutritional formulation according to claim 25 , wherein the source of ARA comprises single-celled organisms.
27 . The nutritional formulation according to claim 25 , wherein the sources of both DHA and ARA comprise single-celled organisms.
28 . The nutritional formulation according to claim 25 , wherein the ratio of ARA:DHA in the nutritional formulation ranges from about 10:1 to about 1:10.
29 . The nutritional formulation according to claim 25 , wherein the ratio of ARA:DHA in the nutritional formulation ranges from about 2:1 to about 1:3.
30 . The nutritional formulation according to claim 25 , wherein the ratio of ARA:DHA in the nutritional formulation is about 1:2.
31 . The nutritional formulation according to claim 25 , wherein the nutritional formulation comprises ARA in an amount of from about 4 mg to about 100 mg per 100 kcal nutritional formulation.
32 . The nutritional formulation according to claim 25 , wherein the nutritional formulation comprises ARA in an amount of from about 10 mg to about 67 mg per 100 kcal nutritional formulation.
33 . The nutritional formulation according to claim 25 , wherein the nutritional formulation comprises ARA in an amount of from about 30 mg to about 40 mg per 100 kcal nutritional formulation.
34 . The nutritional formulation according to claim 25 , wherein the nutritional formulation contains substantially no EPA.
35 . The nutritional formulation according to claim 1 , wherein the nutritional formulation is an infant formula.
36 . The nutritional formulation according to claim 1 , wherein the nutritional formulation is a children's nutritional product.
37 . A reconstituted nutritional formulation comprising a lipid source, a carbohydrate source, a protein equivalent source, and about 5% of an emulsifying agent comprising OSA-modified tapioca starch wherein the reconstituted nutritional formulation contains less than about 5 ppm non-protein nitrogen.
38 . The nutritional formulation according to claim 37 , wherein the reconstituted nutritional formulation contains less than about 4 ppm non-protein nitrogen.
39 . The nutritional formulation according to claim 37 , wherein the reconstituted nutritional formulation contains less than about 3.5 ppm non-protein nitrogen.
40 . A method for treating a subject with protein allergies, the method comprising feeding the subject the nutritional formulation of claim 1 .
41 . The method according to claim 40 , wherein the subject is an infant.
42 . The method according to claim 40 , wherein the subject is a child.
43 . A method for treating a subject with protein intolerances, the method comprising feeding the subject the nutritional formulation of claim 1 .
44 . The method according to claim 43 , wherein the subject is an infant.
45 . The method according to claim 43 , wherein the subject is a child.